The Latest Breaking News on Pharma

Chemical and consumer product manufacturer 3M has agreed to pay $6 billion to settle numerous lawsuits from U.S. service members who say they experienced hearing loss or other serious injuries from using earplugs made by the company

The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drugmakers are fighting the negotiations with lawsuits.

Owing to the critical medical needs, the lookout for new technologies to deal with future advancements is at its peak. Breakthrough innovations, revolutionary treatments, and a booming industry align to make biotech stocks a potential goldmine for savvy investors. Therefore, it could be wise to invest in quality biotech stocks…

Thanks to the non-cyclical nature and the increasing demand for healthcare services, the healthcare industry should continue to brave most market challenges. Hence, it could be an opportune time to explore dominating medical stocks: Elevance Health (ELV), Centene Corp. (CNC), and Molina Healthcare (MOH), which might garner substantial returns for…

The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.…

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

CEOs received average increase of 16% while pay of many working for them failed to keep up with inflation

Businesses relying on the popular but contentious payments model are finding their operations increasingly difficult to stack up, reports Andrew Bevin.

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….